



\$150
[Handwritten signature]

PATENT
Docket No.: 12475/50502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : WARRELL et al.
SERIAL NO. : 10/750,742
FILED : December 31, 2003
FOR : Combination of Gallium Compounds with Non-Chemotherapeutic Anticancer Agents in the Treatment of Neoplasia
EXAMINER : B. Fetterolf
GROUP ART UNIT : 1642

FEE TRANSMITTAL

Applicant claims small entity status.

Applicants' response to the Office Action mailed November 1, 2005, is filed herewith and adds two dependent claims to the subject patent application.

Extra Claim Fees:

Total Claims <u>After Amendment</u>	Total Claims <u>Previously Paid For</u>	Extra Claims	Fee	Fee Paid
152	-	150	= 2 x \$25.00	= \$50.00

The Director is hereby authorized to charge the fee indicated above, charge any underpayments of fees, charge any additional fee(s), and credit any overpayments to Deposit Account 503154. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Donna R. Fugit

Donna R. Fugit, Ph.D.
Reg. No. 32,135

Genta Incorporated
Two Connell Drive
Berkeley Heights, NJ 07922
Tel. (908) 219-3195
Fax (908) 286-5982

Date: *Dec. 31, 2005*



PATENT
Docket No.: 12475/50502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Raymond P. WARRELL, Jr., et al.
SERIAL NO. : 10/750,742
FILED : December 31, 2003
FOR : Combination of Gallium Compounds with Non-Chemotherapeutic Anticancer Agents in the Treatment of Neoplasia
EXAMINER : B. Fetterolf
GROUP ART UNIT : 1642

Mail Stop Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: Dec. 31, 2005 *Donna R. Fugit*
Donna R. Fugit, Ph.D.
Reg. No. 32,135

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

SIR:

This is in response to the Office Action mailed November 1, 2005, requiring restriction and election of species in the subject patent application.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 15 of this paper.